SOPHiA GENETICS insider files Form 144 to sell 684 shares

SOPHiA GENETICS shareholder Daan Guido Maria Van Well has filed a Form 144 notice for a proposed sale of common stock.

Rhea-AI Filing Summary

SOPHiA GENETICS shareholder Daan Guido Maria Van Well has filed a Form 144 notice for a proposed sale of common stock. The filing covers 684 common shares to be sold through Morgan Stanley Smith Barney LLC on or about 01/20/2026, with an aggregate market value of $3,727.80 based on the price used in the notice, and notes that 67,847,058 common shares were outstanding.

The 684 shares come from restricted stock units acquired from the issuer on 01/18/2026. The filing also lists recent activity under Rule 10b5-1: sales of 2,056 shares for $9,758.39 on 01/06/2026, 2,051 shares for $9,451.21 on 01/05/2026, 684 shares for $3,168.01 on 12/19/2025, and 685 shares for $2,755.14 on 11/19/2025, all in SOPHiA GENETICS common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for SOPH disclose?

The Form 144 discloses that Daan Guido Maria Van Well has given notice of a proposed sale of 684 shares of SOPHiA GENETICS common stock, to be sold through Morgan Stanley Smith Barney LLC on or about 01/20/2026 on the NASDAQ exchange.

How many SOPHiA GENETICS (SOPH) shares are covered by this proposed sale?

The notice covers a proposed sale of 684 common shares of SOPHiA GENETICS, with an indicated aggregate market value of $3,727.80 in the filing.

What is the source of the SOPH shares to be sold under this Form 144?

The 684 shares proposed for sale come from restricted stock units in SOPHiA GENETICS common stock that were acquired from the issuer on 01/18/2026.

What recent 10b5-1 sales by the SOPH insider are listed?

The filing lists Rule 10b5-1 sales for Daan Guido Maria Van Well of SOPHiA GENETICS common stock: 2,056 shares for $9,758.39 on 01/06/2026, 2,051 shares for $9,451.21 on 01/05/2026, 684 shares for $3,168.01 on 12/19/2025, and 685 shares for $2,755.14 on 11/19/2025.

How many SOPHiA GENETICS shares were outstanding when this Form 144 was prepared?

The Form 144 states that 67,847,058 SOPHiA GENETICS common shares were outstanding, providing context for the 684 shares covered by the proposed sale.

Which broker is handling the proposed Form 144 sale for SOPH shares?

The proposed sale of the 684 SOPHiA GENETICS common shares is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/20/2026 - 04:25 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002006414
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	SOPHIA GENETICS SA
SEC File Number	001-40627
Address of Issuer	La Piece 12 ch-1180 Rolle SWITZERLAND 00000
Phone	41216941060
Name of Person for Whose Account the Securities are To Be Sold	DAAN GUIDO MARIA VAN WELL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	684	3727.80	67847058	01/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/18/2026	Restricted Stock Units	Issuer			684	01/18/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for DAAN GUIDO MARIA VAN WELL La Piece 12 ch-1180 Rolle V8 00000	Common	01/06/2026	2056	9758.39
10b5-1 Sales for DAAN GUIDO MARIA VAN WELL La Piece 12 ch-1180 Rolle V8 00000	Common	01/05/2026	2051	9451.21
10b5-1 Sales for DAAN GUIDO MARIA VAN WELL La Piece 12 ch-1180 Rolle V8 00000	Common	12/19/2025	684	3168.01
10b5-1 Sales for DAAN GUIDO MARIA VAN WELL La Piece 12 ch-1180 Rolle V8 00000	Common	11/19/2025	685	2755.14

144: Remarks and Signature

Remarks
Date of Notice	01/20/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/03/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daan Guido Maria Van Well
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)